Home › Funds › BAKER BROS. ADVISORS LP › CLDX

BAKER BROS. ADVISORS LP position in CLDX

CELLDEX THERAPEUTICS INC NEW · Health Care

BAKER BROS. ADVISORS LP reported holding 1,182,611 shares of CLDX (CELLDEX THERAPEUTICS INC NEW) in its Q2 2026 13F filing — a position valued at US$44.0M, representing 0.23% of its reported portfolio and ranking #39 among its reported holdings. BAKER BROS. ADVISORS LP has disclosed CLDX holdings in 11 of the last 11 reported quarters, going back to Q4 2023.

Latest position (Q2 2026)1.18M sh
Reported value held$44.00M
Portfolio Weight0.23%
First reportedQ4 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How BAKER BROS. ADVISORS LP's CLDX position evolved

BAKER BROS. ADVISORS LP first disclosed a stake in CLDX in Q4 2023 at 247,644 shares (US$9.8M). The position peaked in Q2 2026 at 1,182,611 shares, worth US$44.0M. Across 11 filings, BAKER BROS. ADVISORS LP increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 8 time(s). The most recent filing (Q2 2026) shows 1,182,611 shares valued at US$44.0M — an increase of 517,241 shares quarter over quarter.. Notable position changes include a 169% increase in Q2 2025 (shares rose 27% over the following quarter), a 78% increase in Q2 2026 (shares fell 13% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 247.64K $9.82M New
Q1 2024 247.64K $10.39M Hold
Q2 2024 247.64K $9.17M Hold
Q3 2024 247.64K $8.42M Hold
Q4 2024 247.64K $6.26M Hold
Q1 2025 247.64K $4.49M Hold
Q2 2025 665.37K $13.54M Add
Q3 2025 665.37K $17.21M Hold
Q4 2025 665.37K $18.07M Hold
Q1 2026 665.37K $21.11M Hold
Q2 2026 1.18M $44.00M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CLDX and 13F data

CLDX (CELLDEX THERAPEUTICS INC NEW) is a Health Care company. 43 other funds we track also report a position in CLDX — the largest reported positions include Kynam Capital Management, LP (US$198.1M), Deep Track Capital, LP (US$109.4M), Logos Global Management LP (US$78.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CLDX

All CLDX fund holders →

FAQ

How long has BAKER BROS. ADVISORS LP held CLDX?

BAKER BROS. ADVISORS LP has disclosed CLDX holdings in 11 of the last 11 reported quarters, going back to Q4 2023.

What is BAKER BROS. ADVISORS LP's current position in CLDX?

As of Q2 2026, BAKER BROS. ADVISORS LP holds 1.18M shares of CLDX (CELLDEX THERAPEUTICS INC NEW), valued at $44.00M, representing 0.23% of its reported portfolio and ranking #39.

Has BAKER BROS. ADVISORS LP been buying or selling CLDX?

In the latest 13F filing (Q2 2026), BAKER BROS. ADVISORS LP increased its position in CLDX. The position peaked in Q2 2026 at 1.18M shares.

Which other funds hold CLDX?

Other major institutional holders of CLDX include Kynam Capital Management, LP, Deep Track Capital, LP, Logos Global Management LP, among 43 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.